Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
BUSINESS
Transfer of Vaccine, Blood Biz under Negotiation, All Directors to Exit in June: Kaketsuken
The Chemo-Sero-Therapeutic Research Institute will place the highest priority on recovering its operations in its quake-hit home prefecture of Kumamoto, while continuing talks to transfer its vaccine and blood product businesses to another company and revamp its organization. The institute,…
To read the full story
Related Article
- Kaketsuken’s Business Transfer Necessary: MHLW Official
September 9, 2016
- MHLW to Gauge Possible Deregulation of Plasma Export Restriction towards FY2018: Blood Division Chief
August 3, 2016
- Kaketsuken Continues to Suspend Production as Huge Damages Found
April 22, 2016
- Kaketsuken in Talks to Transfer Vaccine Biz to Astellas
April 8, 2016
- Kaketsuken Ordered Record 110-Day Suspension, Shiozaki Says He Won’t Allow It to Remain As-Is
January 12, 2016
- Kaketsuken Faces 110-Day Biz Suspension, Urged to Dissolve as Legal Entity
January 8, 2016
- Probe Finds Kaketsuken’s GMP Violations “Extremely Malicious”, MHLW to Impose Penalty
December 3, 2015
BUSINESS
- Lilly Confirms Orforglipron Diabetes Filings in US, Japan
August 7, 2026
- Takeda Snares US Approval for Orzeyful in Narcolepsy Type 1
August 7, 2026
- Inrebic Expands First-Line Treatment Options for Myelofibrosis: Expert
August 7, 2026
- Meiji Pharma Drops Hiyasta Development in B-Cell NHL
August 7, 2026
- AstraZeneca Japan Chief Says MFN Response Requires Drug Pricing Reform
August 5, 2026
Japan’s pharmaceutical policy appears to be entering a new phase. The government’s newly approved honebuto policy and growth strategy both…
A few weeks ago, I had coffee with a very talented executive. Let’s call him Kenji. He has a great job, a big salary, and a solid team. But he was unhappy. He felt bored and wanted a new challenge.…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…